Alerts will be sent to your verified email
Verify Email
TRIMURTHI
|
Novelix Pharma
|
Positron Energy
|
Balaxi Pharma.
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
0.0 | 28.49 % | 28.02 % |
|
5yr average Equity Multiplier
|
1.26 | 2.58 | 1.4 |
|
5yr Average Asset Turnover Ratio
|
0.84 | 2.01 | 1.43 |
|
5yr Avg Net Profit Margin
|
-14.11 % | 5.86 % | 11.03 % |
|
Price to Book
|
6.39 | 1.45 | 0.47 |
|
P/E
|
61.17 | 6.41 | 11.8 |
|
5yr Avg Cash Conversion Cycle
|
29.1 Days | 12.01 Days | 154.28 Days |
|
Inventory Days
|
34.04 Days | 14.67 Days | 87.41 Days |
|
Days Receivable
|
55.38 Days | 25.28 Days | 103.86 Days |
|
Days Payable
|
55.7 Days | 26.53 Days | 63.18 Days |
|
5yr Average Interest Coverage Ratio
|
-17.77 | 12.35 | 57.05 |
|
5yr Avg ROCE
|
-15.4 % | 25.69 % | 36.52 % |
|
5yr Avg Operating Profit Margin
|
-16.49 % | 7.82 % | 16.64 % |
|
5 yr average Debt to Equity
|
0.05 | 0.7 | 0.09 |
|
5yr CAGR Net Profit
|
35.78 % | 138.58 % | -5.76 % |
|
5yr Average Return on Assets
|
-13.36 % | 11.43 % | 18.47 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
51.98 % | 72.04 % | 65.99 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-14.94 % | 0.04 % | -6.7 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
|
Novelix Pharma
|
Positron Energy
|
Balaxi Pharma.
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|